Trial Profile

A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucidinostat (Primary)
Indications Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors HUYA Bioscience International

Most Recent Events

18 Sep 2022 Preliminary results assessing safety and efficacy published in the Japanese Journal of Clinical Oncology
10 Jan 2017 Status changed from active, no longer recruiting to completed.
06 Dec 2016 Preliminary results assessing the efficacy, safety and maximum tolerated dose (MTD) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com